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Abstract-Alkylation of sarcosine with 4-chloro-nitrobenzo-2-oxa-1,3-diazole (NBD-chloride) furnished 
a fluorescent tag that was coupled with a tetrahydrothebaine derivative and /I-naltrexamine, respectively, 
to yield the fluorescent opioids 7~-(1R)-l-hydroxy-l-methyl-3-(4-hydroxyphenyl)-propyl]-6,14-endo- 
ethenotetrahydrothebaine NBD-sarcosinate (ASM-5-10) and N-cyclopropylmethyl-3-hydroxy-14& 
hydroxy-6/3-(NBD sarcosinyl)-amino-epoxymorphinan (ASM-5-67). The fluorescence intensity of the 
novel opioids allowed their detection at subnanomolar concentrations, and was dependent on the 
polarity of the solvent. Maximum quantum yield was obtained in ethyl acetate and ethanol, and minimal 
fluorescence in heptane and water. Compounds ASMJ-10 and ASM-5-67 displaced the opioid receptor 
binding of [ 3H]Tyr-D-Ala-Gly-(Me)Phe-Gly-ol in monkey brain membranes with ICY,, values of 8.4 and 
1.5 nM, respectively. Whereas ASM-5-67 bound to p, 6, and K receptors with comparable affinities, 
ASM-5-10 was p-selective, with selectivity indices (ratio of respective rcsO values) of 0.04 for both p/u/6 
and F/K. The sodium response ratio in binding revealed a pronounced agonist property of ASMJ-10. 
Both opioids were lipophilic, with octanol-water partition coefficients (log Parr) of 2.8 (ASMJ-10) and 
1.0 (ASM-5-67). ASM-5-10 exhibited particularly strong membrane retentton that was not reversible 
by four washes. Their favorable characteristics in fluorescence, receptor binding, and membrane 
interaction make these newly developed ligands useful molecular probes to study opioid receptor 
mechanisms. 
The usefulness of fluorescent ligands to probe 
receptor mechanisms is well documented. The 
applications include the histochemical localization 
of receptors, their visualization on cell surfaces, 
quantitation of receptor mobility by the technique 
of fluorescence recovery after photobleaching, 
and fluorescent energy transfer experiments to 
characterize the receptor environment, e.g. the lipid 
boundary layer in membranes, or the topography of 
binding sites on isolated receptor molecules. Opioids 
containing different fluorophores, including dansyl 
[l], rhodamine [2], fluorescein [3], and pyrene [4], 
have been synthesized previously. The utility of 
dansylated compounds is limited due to intense 
autofluorescence of brain tissue [5] and the inhibition 
of opioid receptors at wavelengths required for the 
excitation of this fluorescent tag [6]. Rhodamine and 
fluorescein are bulky molecules likely to impair the 
lateral diffusion of the ligand-occupied receptor in 
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the membrane, and the attenuation of pyrene 
fluorescence in solvents of intermediate polarity [7] 
may limit the contribution of signal derived from 
the occupation of membrane receptors by such ligand 
in proportion to that of free ligand. 
The fluorescence characteristics and molecular 
properties of 7-nitrobenzo-2-oxa-1,3-diazole 
(NBDII), when coupled to an amine, suggested that 
it may be a useful tag to study opioid receptor 
mechanisms. NBD fluorescence is complementary 
to rhodamine for fluorescent energy transfer, e.g. 
between receptor and GTP binding protein [8], and 
its dependence on the polarity of the respective 
environment favors the membrane receptor-bound 
ligand [9, lo]. NBD-labeled compounds have been 
used to visualize the y-aminobutyric acid (GABA)- 
benzodiazepine receptor on rat spinal cord cells: 
fluorescence of bound ligand was enhanced 35fold 
over background, allowing the measurement of 
receptor mobility by fluorescence recovery after 
photobleaching [ll]. The NBD tag has also been 
attached to Padrenergic antagonists [9,12], and 
estrogen and progestin derivatives [lo]. We have in 
this study synthesized two opioids containing the 
NBD residue, and have studied their characteristics 
as ligands of opioid receptors. The obtained results 
show that these novel fluorescent opioids represent 
valuable probes to study opioid receptor mechanisms. 
Materials 
MATERIALS AND METHODS 
[3H]Tyr - D -Ala - Gly - (Me)Phe - Gly - 01([~f-I]- 
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+ H-N-CH,-COOH - 
6 
Fig. 1. Scheme of synthesis of fluorescent opioids. Details of the procedures are described under 
Materials and Methods. Compounds 5 and 6 represent the opioids ASM-5-67 and ASM-5-10 evaluated 
in this study. 
(DAMGO) and [3H][D-Penz,D-Pen5]enkephalin 
(~3H]DPRPE) were purchased from the Amersham 
Corp., and [3H]U69,593 was obtained from the New 
England Nuclear Corp. The unlabeled opioids were 
obtained through the Narcotic Drug and Opiate 
Peptide Basic Research Center at the University of 
Michigan. The other biochemicals were from the 
Sigma Chemical Co. 
Synthesis of fluorescent opioids 
Melting points were taken on a laboratory Mel- 
Temp apparatus. The ‘H NMR spectra were run on 
a Varian XL200 spectrometer using (CH&Si as the 
internal standard. IR spectra were run on a Perkin- 
Elmer model 298 infrared spectrophotometer, and 
microanalyses were performed by Atlantic Microlab, 
inc., Norcross, GA. 
Pre~arut~on of N-4-(7-nifro~e~zo-2-oxa-l,3-d~a- 
rolyl)-sarcosine (Fig. 1, compound 3). A solution of 
500 mg (2.5 mmol) of 4-chloro-7-nitrobenzo-2-oxa- 
1,3-diazole (NED-chloride, Fig. 1, compound 1) in 
20mL methanol was added to the stirred solution 
of 225 mg (2.5 mmol) sarcosine (Fig. 1, compound 
2) and 210 mg (2.5 mmol) of sodium bicarbonate in 
5 mL of water. The mixture was stirred at 55” for 
3 hr, the methanol was evaporated in vacua, and 
the residue was disolved in 20 mL of water containing 
265 mg (2.5 mmol) sodium bicarbonate. The basic 
solution was then washed with 50 mL ethyl acetate, 
and the aqueous phase was filtered and neutralized 
with 7SmL (7.5mmol) of 1 N HCI. After 
concentration of the neutral solution at room 
temperature, the desired NBD-sarcosine crystallized. 
The precipitate was filtered, washed with a little 
water and then with ether, and dried to give 300 mg 
of product with a melting point of 182-183”. Further 
concentration of the mother liquor gave a second 
crop of desired product. Total yield: 375 mg (60%), 
which melted at 185-187” after recrystallization from 
methanol. Calculated analysis (in percent) for 
CsHsN@s: C, 42.86; II, 3.20; N, 22.22. Found: C, 
42.96; H, 3.20; N, 22.16. 
Preparation of NBD-sarcosine-acid chloride (Fig. 
1, compound4). NBD-sarcosine (34 mg; 0.135 mmol) 
was suspended in 5 mL of dry methylene chloride, 
and 0.5 g (4.0 mmol) of thionyl chloride was added. 
The mixture was heated under reflux for 20min. 
The resulting clear solution was then distilled in 
uacuo until all excess of thionyl chloride was 
removed. The oily residue was dissolved in 10 mL 
of dry methylene chloride and again evaporated in 
uacuo to remove traces of thionyl chloride. The 
desired acid chloride was obtained as a dark red film 
and used without further purification. 
preparation of ASP-5-67, N-~y~lopropyImethy~- 
3 - hydroxy - 140 - hydroxy - 68 - {NBD sarcosinyl) - 
amino-epoxymorphinan (Fig. 1, compound 5). In a 
flask equipped with a magnetic stirrer and protected 
from moisture, 50 mg (0.12 mmol) of j?- 
naltrexamine * HCl was suspended in 10 mL of dry 
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methylene chloride and then 40mg (0.4mmol) 
triethylamine was added. To the stirred mixture a 
solution of the above acid chloride (0.13 mmol) in 
5 mL of dry methylene chloride was added dropwise 
during 5 min at room temperature, and stirring was 
continued for 24 hr. The reaction solution was 
diluted with methylene chloride, and washed with 
saturated sodium bicarbonate solution and with 
water. The methylene chloride phase was filtered 
and evaporated in vacua to give 56 mg crude product 
that was chromatographed on preparative TLC 
plates (silica gel/ethyl acetate : methanol 9 : 1) to give 
35 mg (51%) of TLC-pure desired amide. Melting 
point: 230-240” (decomposition). Calculated analysis 
(in percent) for CZ9Hs2N607.HZO: C, 58.58; H, 
5.76; N, 14.14. Found: C, 59.01; H, 5.74; N, 14.07. 
Preparation of AsM-5-10,7a-[(lR)-l-hydroxy-l- 
methyl - 3 - (4 - hydroxyphenyl) -propylj - 6,14 - endo - 
ethenotetrahydrothebaine NBD-sarcosinate (Fig. 1, 
compound 6). To the stirred solution of 54mg 
(0.198 mmol) NBD-sarcosine-acid chloride in 15 mL 
of dry methylene chloride, a solution of 90mg 
(0.178 mmol) of 7Lu-[(lR-1-hydroxy-1-methyl-3-(4- 
hydroxyphenyl) - propyl] - 6,14 - endo - etheno- 
tetrahydrothebaine in 10mL of dry methylene 
chloride was added at room temperature followed 
by the addition of 25 mg (0.2mmol) of 4- 
dimethylaminopyridine. Stirring at room tem- 
perature with exclusion of moisture was continued 
overnight. The reaction mixture was then diluted 
with methylene chloride and washed with saturated 
sodium bicarbonate solution and with water. The 
organic layer was evaporated in vacua and the 
residue was chromatographed on silica gel plates 
using ethyl acetate as the developing solvent to give 
96 mg (73%) of TLC-pure phenolic ester. The latter 
was dissolved in ethyl acetate, filtered and triturated 
with ether to give an orange-colored solid that was 
filtered, washed with diethyl ether and dried. Melting 
point: 145-155” (decomposition). Calculated analysis 
(in percent) for C40H43NS09. l/4 H20: C, 64.72; 
H, 5.90; N, 9.43. Found: C, 64.62; H, 5.92; N, 9.40. 
Membrane isolation 
Membranes from rhesus monkey cortex were 
prepared as previously described [13]. The protein 
concentration of the final membrane suspensions 
was approximately 0.6 mg/mL as determined by the 
method of Lowry et al. [14] using bovine serum 
albumin as standard. 
Opioid receptor assay 
The procedure that was followed was described 
previously in detail [13,15]. The assay is based on 
the displacement of a receptor-selective radiolabeled 
opioid by the tested compounds. Specific binding of 
the radioligand was defined as the difference between 
binding in the absence and presence of an appropriate 
excess of the corresponding unlabeled opioid. After 
incubation at 25” to reach binding equilibrium, the 
samples were quickly filtered, washed, and subjected 
to liquid scintillation counting. The affinity of the 
investigated ligands in binding to opioid receptor 
was expressed as the concentration that inhibited 
50% of maximal binding of a given radiolabeled 
ligand (IC&. Binding selectivity was expressed as 
selectivity index, representing the ratio of 1c50 values 
of a compound in inhibiting the specific binding of 
two selective radiolabeled ligands. The sodium 
response ratio for a given compound corresponded 
to the ratio of the respective lCso values obtained in 
the presence and absence of 150 mM NaCl. 
Membrane retention 
Sixteen milliliters of a suspension of brain 
membranes in 50mM Tris*HCl, pH 7.4, was 
incubated with a 100nM concentration of the 
fluorescent opioids for 60 min at 25”. Aliquots were 
then removed for receptor binding and protein assay, 
and the residual suspension was diluted with 25 mL 
of ice-cold buffer and centrifuged at 20,OOOg for 
15 min. The resulting pellet was resuspended with 
buffer to the original protein concentration and an 
aliquot removed for the determination of bound 
ligand and protein concentration. The washes were 
repeated subsequently and samples removed for 
binding and protein assays after each wash. Receptor 
binding was carried out by the displacement of 
0.5 nM [3H]DAMG0 as described above. 
Lipid-water partition coefficients (log PaPP) 
These parameters were determined by a recently 
developed micromethod requiring minute amounts 
of the opioids [ 161. Briefly, following the partitioning 
of the opioid (low- or sub-micromolar solution) 
between n-octanol and Tris.HCl buffer, pH 7.4, at 
25”, the concentration remaining in the aqueous 
phase was determined using an opioid receptor 
binding assay based on the displacement by the 
tested opioids of bound [3H]DAMG0 in brain 
membranes. 
Fluorescence spectra 
Fluorescence was measured on a PTI Alphascan 
fluorometer with excitation and emission slits at 
5 nm. The fluorescent opioids were solubilized with 
either 50 mM Tris.HCl, pH 7.4, 100% ethanol, 
ethyl acetate, or heptane. As shown previously 
[9, lo], the excitation wavelengths were solvent 
specific: their values are listed in the legend to 
Fig. 2. 
RESULTS 
Synthesis and fluorescent properties 
The fluorescent opioids were prepared as described 
under Materials and Methods and depicted in Fig. 
1. The spectral properties of fluorescent opioids 
were determined in solvents of various polarities 
(Fig. 2). Compared to solutions of intermediate 
polarity, the excitation and emission maxima of the 
compounds were shifted to longer wavelengths in 
polar and apolar solvents. The intensity of NBD 
fluorescence was minimal in Tris . HCl buffer, pH 
7.4, and heptane, but was greatly increased in 
ethanol and ethyl acetate. Compared to Tris buffer, 
the enhancement factor was 12- and 23-fold and lo- 
and 7-fold for ASM-5-10 and ASM-5-67 in ethanol 
and ethyl acetate, respectively. Relative to heptane, 
the quantum yield of fluorescence in ethanol and 
ethyl acetate was amplified 60- and lo&fold for 
ASM-5-10 and 24- and ldfold for ASM-5-67. In 
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500 520 540 
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Fig. 2. Fluorescence spectra of novel opioids. Shown are 
the fluorescence intensities of compounds ASM-5-10 (10) 
and ASM-5-67 (67) dissolved at a 100 nM concentration in 
ethyl acetate (EA), ethanol (E), heptane (H) and aqueous 
buffer (Tris) medium (W). The corresponding wavelengths 
for the excitation and emission maxima were (nm): 486, 
526 (E); 496, 536 (H); 480, 533 (W). In EA the two 
wavelengths were 456 and 517 for ASMJ-10 and 456 and 
526 for ASM-5-67. 
ethanol, the limit of detection of the fluorescent 
signal was less than 1 nM for both ligands. 
Fig. 3. Displacement of receptor-selective opioids by the 
fluorescent compounds. Shown is the inhibition by ASM- 
5-10 (a) and ASM-5-67 (a) of the specific binding of 
0.5 nM [3H]DAMG0 (A), 1.5 nM [3H]DPDPE (B), and 
1.5 nM [3H]U69,593 (C) in monkey brain membranes. 
Plotted is extent inhibition at different concentrations of 
the fluorescent opioids. The corresponding rcSo values are 
listed in Table 1. Shown are mean values of three 
Receptor binding experiments, each carried out in duplicate. 
While ASM-S-67 bound with high affinity to p, S, 
and K opioid receptors, ASMS-10 exhibited 
considerable selectivity for the p receptor (Fig. 3 
and Table 1). The slightly higher slope factors of 
ASM-S-10 are likely to reflect the strong lipophilicity 
of this compound, as discussed later. The cor- 
responding selectivity indices showed that ASMJ- 
10 preferred fi sites over those of 6 or K specificity 
to a similar extent. The results of ligand binding are 
expressed as ~~~~ in order to allow direct comparison 
with binding affinities and receptor selectivities of 
various opioids determined in our laboratory [13]. 
The concentration of radioligand in the binding assay 
was selected to be low relative to its KD in order to 
minimize the divergence between the obtained lcsO 
and true Ki. Indeed, the binding selectivities of 
fluorescent opioids calculated on the basis of their 
Ki, rather than ICS~, values were virtually identical 
to the results listed in Table 1: v/S and ,U/K indices 
for ASM-5-10 were 0.036 and 0.043, and for ASM- 
5-67 they were 0,396 and 0.525, respectively. Sodium 
attenuated the binding affinity of ASM-5-10 at the 
,u receptor (Table 1) to an extent similar to that 
obtained in the binding of the opioid agonists 
DAMGO or sufentanil: these compounds had 
sodium ratios of 1.36 and 1.38, respectively, in 
contrast to naloxone whose ratio was 0.49 [13]. 
morphine, determined by the identical method, were 
2.79 and -0.21 [16]. 
Considering the strongly hydrophobic nature of 
the fluorescent opioids, their retention in the 
membrane was assessed by the recovery of [3H]- 
DAMGO binding after repeated washing of 
membranes incubated with receptor-saturating con- 
centrations of fluorescent ligand. While ASM-5-67 
was readily washed out from membranes, opioid 
receptor binding in membranes incubated with ASM- 
5-10 was still inhibited by 75% after four washes 
(Fig. 4). 
DISCUSSION 
On the basis of their n-octanol/water partitions, 
the fluorescent opioids were found to be strongly 
lipophilic with log P values of 2.8 and 1.0 for 
compounds ASMS-10 and ASM-5-67, respectively. 
The corresponding values for etorphine and 
Fluorescent ligands of various receptor systems, 
including the LY- and padrenergic, adenosine, 
glucagon, steroid, dopamine, and benzodi~epine 
have been used successfully to study receptor 
function [e.g. Ref. 171. Opioids tagged with different 
fluorophores were also synthesized and their 
properties evaluated. While providing interesting 
new insights, e.g. the clustering of opioid receptors 
in neuroblastoma cells using a rhodamine-tagged 
enkephalin derivative [Z], the major drawback of 
most of these compounds was their impaired affinity 
and opioid character in binding to opioid receptors. 
The attachment of fluorescein to the C-6 position of 
oxymorphone, naltrexone, or naloxone resulted in 
a 16- to 20-fold attenuation of receptor binding 
affinity [3]. In addition, the attachment of fluorescein 
1 1 
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ICSO (uM) Selectivity index 
Sodium 
P s K p/h PIK ratio 
8.40 2 0.71 216 * 2.31 193 + 4.05 0.04 0.04 1.55 
(1.10) (1.28) (1.12) 
1.53 f 0.10 3.81 rt 0.12 2.83 * 0.09 0.40 0.54 1.00 
(1.02) (1.09) (0.98) 
The effects of compounds ASM-5-10 and ASM-5-67 on the opioid receptor binding of j3H]- 
DAMGO @-selective), [3H]DPDPE (&selective)aand [3H]U69,593 (K-selective) in monkey brain 
membranes were determined, in the absence of NaCI, as described under Materials and Methods 
and in the legend to Fig. 3. The ICKY values and slope factors were determined by linear regression 
analysis from corresponding Hill plots, relating percent inhibition of specific radioligand binding to 
five concentrations of the competing opioid. All the regression coefficients (r2) were higher than 
0.98. Shown are the mean +: SEM values for ICKY and corresponding slope factors (in parentheses) 
obtained in three experiments, each carried out in duplicate. The selectivity indices represent the 
ratio of respective lcso values of a compound in inhibiting the binding of radiolabeled selective 
opioids, e.g. [‘H]DAMGO/[3H]DPRPE for the p/S index. Also listed is the sodium ratio, calculated 
as the ratio of lcso obtained in displacing 0.5 nM [3H]DAMG0 in the presence and absence of 
150 mM NaCI. 
NUMBER OF WASHES 
Fig. 4. Membrane retention of fluorescent opioids. A 
suspension of brain membranes in Tris.HCI buffer, pH 
7.4, was incubated with a 100 nM concentration of ASM- 
S-10 (0) or ASM-5-67 (W). After incubation for 60 min at 
25”, the suspension was centrifuged, the pellet was 
resuspended with 50 mM Tris .HCI, pH 7.4, and aliquots 
were included in the opioid receptor assay using [3H]- 
DAMGO. The residual membrane suspension was 
subjected to repeated sequences of the washout procedure 
and opioid receptor assay, as described under Materials 
and Methods. In the initial control membranes, the specific 
binding of [3H]DAMG0 was 73 fmol/mg protein. Shown 
are the averages of results obtained in two experiments, 
each carried out in duplicate. 
to the opioid antagonists naloxone and naltrexone 
attenuated their antagonist property [18]. The 
incorporation of the fluorescent amino acid ~-1. 
pyrenylalanine into leucine-enkephalin at positions 
4 or 5 preserved recognition at h or &opioid receptors 
although, again, with diminished affinity: in 
displacing [3H]DAMG0, the 4- and 5-substituted 
enkephalins had 1~50 values of 60 and 113 nM, 
respectively [4]. Interestingly, the opioid nature of 
the enkephalin molecule was also preserved 
following the substitution of its tyrosyl residue by 
pyrenylalanine [7]. L-Tyrosine in position 1 was 
considered essential for recognition of enkephalins 
at the opioid receptor. 
In the work described here, we have synthesized 
two fluorescent opioid alkaloids containing the NBD 
residue. The favorable fluorescent characteristics 
and molecular properties of this fluorophore have 
previously led to its successful use in probes of the 
adrenergic [9] and GABA-benzodiazepine receptors 
[ll]. As shown in the latter studies, as well as in our 
work (Table l), a common feature of the NBD- 
labeled fluorescent ligands appears to be the 
preservation of high affinity in binding to the 
respective receptors. The molecular feature likely to 
contribute to this favorable characteristic of the 
NBD-labeled compounds is the small size of the 
NBD fluorophore, particularly when compared to 
fluorescein or rhodamine. The limited bulk of the 
NBD residue should also offer considerable 
advantage.$ the use of such ligands to study receptor 
dynamics m the plasma membrane. As observed in 
this study, the NBD fluorescence has a strong 
dependence on solvent polarity, a property that aids 
in discriminating between the fluorescence of 
receptor-bound, membrane-solubilized, and free 
ligand in the assay medium. In addition, the 
fluorescence intensity of the two synthesized opioid 
alkaloids enables their detection at subnanomolar 
concentrations. 
The two NBD-labeled opioids exhibited high 
binding affinity and, in part, strong selectivity 
towards the @ opioid receptor. The respective 
properties of ASM-5-10 compared favorably with 
those of morphine [13], a finding not unexpected 
since this fluorescent opioid is an N-methyl compound 
and should, like morphine, be p-selective. On the 
basis of the sodium response ratio in binding, ASM- 
5-67 displayed mixed agonist-antagonist properties, 
but ASM-5-10 showed agonist character. While both 
compounds were hydrophobic, the octanol-water 
partition coefficient of ASMJ-10 was particularly 
high. As shown with buprenorphine, opioids of such 
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pronounced lipophilicity exhibit unusual receptor 
kinetics and time-course of action [19]. To what 
extent the washout pattern of ASMJ-10 reflects 
slow dissociation from receptor or retention in 
hydrophobic membrane compartments remains 
unresolved at this time. It is conceivable to expect 
that high concentrations of a ligand in membrane 
regions around the receptor influence the respective 
lcSo value. On the other hand, a comprehensive 
study of morphinomimetic opioids belonging to 
various chemical classes revealed no correlation 
between binding affinity in rat brain membranes and 
lipophilicity of the compounds [20]. Indeed, the 
characteristics of ASMJ-10 identify it as a useful 
probe to study membrane modulation of opioid 
receptor mechanisms [21]. 
Acknowledgements-The authors thank C. Mousigian for 
technical assistance and R. McLaughlin for typing the 
manuscript. This work was supported by USPHS Grants 
DA01674 (S.A.) and DA04087 (F.M.). 
REFERENCES 
1. Fournie-Zaluski MC, Gacel G, Roques BP, Senault B, 
Lecomte JM, Malfroy B, Swerts JP and Schwartz JC, 
Fluorescent enkephalin derivatives with biological 
activity. Biochem Biophys Res Commun 83: 300-305, 
1978. 
2. Hazum E, Chang KJ, Schecter Y, Wilkinson S 
and Cuatrecasas P, Fluorescent and photoaffinity 
enkephalin derivatives: Preparation and interaction 
with opiate receptors. Biochem Biophys Res Commun 
88: 841-846, 1979. 
3. Kolb VM, Koman A and Terenius L, Fluorescent 
nrobes for ooioid receotors. Life Sci 33: 423-426,1983. 
4. Mihara H, Lee S, Shimohigashi Y, Aoyagi H, Kato T, 
Izumiya N and Costa T, Delta and p opiate receptor 
probes: Fluorescent enkephalins with high receptor 
affinity and specificity. ZXBS Left 193: 35-38, 1985. 
5. Correa FM, Innes ARB, Rouot B, Pasternak GW and 
Snyder SH, Fluorescent probes of tr- and padrenergic 
and opiate receptors: Biochemical and histochemical 
evaluation. Neurosci Lett 16: 47-53, 1980. 
6. Glasel JA and Venn RF, The sensitivity of opiate 
receptors and ligands to short wavelength ultraviolet 
light. Life Sci 29: 221-228, 1981. 
7. Mihara H, Lee S, Shimohigashi Y, Aoyagi H, Kato T, 
Izumiya N and Costa T, Tyr-l-substituted and 
fluorescent Pya-1-enkephalins bind strongly and 
selectively to n and 6 opiate receptors. Biochem 
Biophys Res Commun 136: 1170-1176, 1986. 
8. Barochov-Neori H and Montal M, Rodopsin-G-protein 
interactions monitored by resonance energy transfer. 
Biochemistry 28: 1711-1718. 1989. 
9. Heithier H,. Jaeggi KA, Ward LD, Cantrill RC and 
Helmreich EJM, Synthesis and characterization of 
CGP-12177-NBD: A fluorescent padrenergic receptor 
probe. Biochimie 70: 687-694, 1988. 
10. Carlson KE, Coppey M, Magdelana H and Kat- 
zenellenbogen JA, Receptor binding of NBD-labeled 
fluorescent-estrogens and progestinsm whole cells and 
cell-free preparations. J Steroid Biochem 32: 345-355. 
1989. - . 
11. Velasquez JL, Thompson CL, Barnes EM and 
Angelides K, Distribution and lateral mobility of 
GABA/benzodiazepine receptors on nerve cells. J 
Neurosci 9: 2163-2169, 1989. 
12. Henis YI, Hekman M, Elson EL and Helmreich EJM, 
Lateral motion of /I-receptors in membranes of cultured 
liver cells. Proc Natf Acad Sci USA 79: 2907-2911, 
1982. 
13. Clark MJ, Carter BD and Medzihradsky F, Selectivity 
of liaand binding to ooioid receptors in brain membranes 
from the rat, m&key and guinea pig. Eur J Pharmacol 
148: 343-351, 1988. 
14. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, 
Protein measurement with the Folin phenol reagent. J 
Biol Chem 193: 265-275, 1951. 
1.5. Fischel SV and Medzihradsky F, Scatchard analysis of 
opioid receptor binding. Mol Pharmacol20: 269-279, 
1981. 
16. Medzihradsky F, Emmerson PJ and Mousigian CA, 
Lipophilicity of opioids determined by a novel 
micromethod. J Pharmacol Methodr, in press. 
17. McCabe RT, De Costa BR, Miller RL, Havuryian RH, 
Rice KC and Skolnick P, Characterization of 
benzodiazepine receptors with fluorescent ligands. 
PASEB J 4: 2934-2940, 1990. 
18. Koman A, Kolb VM and Terenius L, Prolonged 
receptor blockade by opioid receptor probes. Pharm 
Res 3: 56-60, 1986. 
19. Hambrook JM and Rance MJ, The interaction of 
buprenorphine with the opiate receptor: Lipophilicity 
as the determining factor in drug-receptor kinetics. In: 
Opiates and Endogenous Opioid Peptides (Ed. 
Kosterlitz HW), pp. 295-301. North-Holland, Amster- 
dam, 1976. 
20. Leysen JE, Gommeren W and Niemegeers CJE, [)H]- 
Sufentanil, a superior ligand for p-opiate receptors: 
Binding properties and regional distribution in rat brain 
and spinal cord. Eur J Pharmacol87: 209-225, 1983. 
21. Medzihradsky F, Modulation of opioid receptor 
mechanisms by membrane lipids: An investigative 
approach. Adv Biosci 75: 41-44, 1989. 
